Podium

Podiums

P4: BENEFITS, VALUE, AND COVERAGE STUDIES

3:45 PM–4:45 PM May 21, 2018 (US - Eastern)

Room: 310 (Level 300)

Description
VA1
15:45 - 16:00

DOES THE TIMING OF A DRUG’S COSTS AND BENEFITS INFLUENCE US PAYER COVERAGE OF SPECIAL DRUGS?

Kim DD, Chambers J, Pope E, Cohen JT, Neumann PJ
Tufts Medical Center, Boston, MA, USA

To view the podium abstract visit:
View Abstract

VA2
16:00 - 16:15

TRENDS IN THE ECONOMIC VALUE OF NEWLY APPROVED CANCER THERAPIES IN THE U.S.

Chen AJ1, Hu X1, Jena AB2, Goldman DP1
1University of Southern California, Los Angeles, CA, USA, 2Harvard Medical School, Boston, MA, USA

To view the podium abstract visit:
View Abstract

VA3
16:15 - 16:30

“IT’S TOUGH TO MAKE PREDICTIONS, ESPECIALLY ABOUT THE FUTURE”: COMPARING LIFE EXPECTANCY PREDICTIONS BASED ON PERIOD VERSUS COHORT LIFE TABLES

Garrison LP, Li M
University of Washington, Seattle, WA, USA

To view the podium abstract visit:
View Abstract

VA4
16:30 - 16:45

ECONOMIC CONSEQUENCES OF ANTI-HCV ANTIVIRAL TREATMENT INVESTMENT FROM THE NHS PERSPECTIVE

Mennini FS1, Marcellusi A1, Viti R1, Kondili L2, Rosato S2, Vella S2, on behalf of PITER collaboration study group .2
1Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome Tor Vergata, Rome, Italy, 2Center for Global Health, Istituto Superiore di Sanità, Rome, Italy

To view the podium abstract visit:
View Abstract

Tags